Curative Biotechnology (CUBT) S-1/A 9 Jan 23 IPO registration (amended) Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2022
Cover [Abstract]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No.3
Entity Registrant Name	Curative Biotechnology, Inc
Entity Central Index Key	0001400271
Entity Primary SIC Number	2836
Entity Tax Identification Number	26-1412177
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	1825 NW Corporate Blvd
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	(561)
Local Phone Number	907-8990
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 636	$ 670,263	$ 160,607
Subscription receivable		25,000
Prepaid expenses	23,716	58,642	1,900,859
Funds receivable on notes payable			70,000
Total current assets	24,352	753,905	2,131,466
Fixed assets:
Property and equipment	6,834	6,834	81,515
Accumulated depreciation	(456)	(114)	(79,177)
Total Fixed Assets	6,378	6,720	2,338
Other assets:
Deferred offering costs	347,908	92,975
Intangible assets, net of amortization	1,629,830	1,558,550	140,300
Total other assets	1,977,738	1,651,525	140,300
Total Assets	2,008,468	2,412,150	2,274,104
Current liabilities:
Accounts payable and accrued liabilities	2,203,434	726,904	97,830
Convertible note payable			128,700
Liability to issue common shares	11,519	3,431	7,400
Short term convertible note payable, net of discounts	621,372		25,415
Third party short term loans, net of discounts			405,646
Short term loan	225,175
Total current liabilities	3,061,500	730,335	664,991
Total Liabilities	3,061,500	730,335	664,991
Commitments and Contingencies
DEFICIENCY IN STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, authorized 200,000,000 shares, zero Series A; Series B, 81,000 shares issued and outstanding	8	8	29
Common stock, $0.0001 par value, authorized 1,100,000,000 shares; 1,429,129 and 1,426,629 shares issued and outstanding	143	143	83
Additional paid-in capital	11,922,430	10,555,143	3,577,875
Accumulated deficit	(31,041,348)	(26,917,036)	(8,099,627)
Total deficiency in stockholders’ equity	(19,118,767)	(16,361,742)	(4,521,640)
Total Liabilities and Deficiency in Stockholders’ Equity	2,008,468	2,412,150	2,274,104
Series A Preferred Stock [Member]
Current liabilities:
Preferred Stock, Series C, 30,000,000 shares issued and outstanding			1,564,251
Series C Preferred Stock [Member]
Current liabilities:
Preferred Stock, Series C, 30,000,000 shares issued and outstanding	$ 18,065,735	$ 18,043,557	$ 4,566,502

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,100,000,000	1,100,000,000	1,100,000,000
Common stock, shares issued	1,429,129	1,426,629	832,500
Common stock, shares outstanding	1,429,129	1,426,629	832,500
Series A Preferred Stock [Member]
Temporary equity, shares issued		0	134,109,750
Temporary equity, shares outstanding		0	134,109,750
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Preferred Stock [Member]
Temporary equity, shares issued	30,000,000	30,000,000	30,000,000
Temporary equity, shares outstanding	30,000,000	30,000,000	30,000,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	81,000	81,000	293,000
Preferred stock, shares outstanding	81,000	81,000	293,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
REVENUES, net
COST OF REVENUES
GROSS MARGIN
OPERATING EXPENSES:
General and administrative expenses	622,252	738,367	1,777,596	3,837,554	4,211,355	4,598,302
Research and development	456,377	125,947	1,548,830	221,087	779,275
Impairment of long-lived assets				15,000	16,958	32,136
Depreciation and amortization	1,988	1,990	5,967	4,755	6,744	5,301
Total operating expenses	1,080,617	866,304	3,332,393	4,078,396	5,014,332	4,635,739
LOSS FROM OPERATIONS	(1,080,617)	(866,304)	(3,332,393)	(4,078,396)	(5,014,332)	(4,635,739)
OTHER (INCOME) EXPENSES
Interest expense	341,873		773,801	176,672	176,672	34,516
Loss on debt settlement		149,350		149,350	149,350
Other income	(4,060)		(4,060)
TOTAL OTHER (INCOME) EXPENSES	337,813	149,350	769,741	326,022	326,022	34,516
Net loss	(1,418,430)	(1,015,654)	(4,102,134)	(4,404,418)	(5,340,354)	(4,670,255)
Series C deemed dividend		(338,880)	(22,178)	(12,521,190)	(13,477,055)	(4,440)
Net loss to common shareholders	$ (1,418,430)	$ (1,354,534)	$ (4,124,312)	$ (16,925,608)	$ (18,817,409)	$ (4,674,695)
Loss per weighted average common share, basic and diluted	$ (0.99)	$ (1)	$ (2.88)	$ (14.13)	$ (15.02)	$ (5.72)
Number of weighted average common shares outstanding, basic and diluted	1,429,129	1,352,654	1,429,029	1,197,760	1,252,454	816,696

Condensed Statement of Deficien

Condensed Statement of Deficiency in Stockholders' Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]		Additional Paid-in Capital [Member]		Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 81	$ 29		$ 3,336,387		$ (3,424,932)	$ (88,435)
Beginning balance, shares at Dec. 31, 2019	807,000	34,402,750
Common shares issued for services				36,800			36,800
Common shares issued for services, shares	4,250
Common shares issued for intangible assets	$ 2			105,998			106,000
Common shares issued for intangible assets, shares	21,250
Warrants issued with notes payable				54,555			54,555
Warrants issued for services				44,135			44,135
Preferred stock Series A issued for services			[1]		[1]			[1]
Preferred stock Series A issued for services, shares		100,000,000
Preferred stock Series C issued for services			[1]		[1]			[1]
Preferred stock Series C issued for services, shares		30,000,000
Series C deemed dividend					[1]	(4,440)	(4,440)
Net loss						(4,670,255)	(4,670,255)
Ending balance, value at Dec. 31, 2020	$ 83	$ 29		3,577,875		(8,099,627)	(4,521,640)
Ending balance, shares at Dec. 31, 2020	832,500	164,402,750
Common shares issued for services	$ 2			518,175			518,177
Common shares issued for services, shares	21,288
Warrants issued with notes payable				9,533			9,533
Warrants issued for services				343,902			343,902
Net loss						(4,404,418)	(4,404,418)
Common shares issued for cash	$ 4			1,024,966			1,025,000
Common shares issued for cash, shares	35,904
Common shares issued for warrant exercise	$ 3			524,997			525,000
Common shares issued for warrant exercise, shares	26,250
Common shares issued to settle debt	$ 3			836,247			836,250
Common shares issued to settle debt, shares	32,344
Shares issued to settle liability issue shares				7,400			7,400
Shares issued to settle liability issue shares, shares	2,500
Option issued for services				218,454			218,454
Deemed dividend						(12,521,190)	(12,521,190)
Series B preferred converted to common	$ 7	$ (21)		14
Series B preferred converted to common, shares	70,666	(212,000)
Series A preferred converted to common	$ 34			1,564,217			1,564,251
Series B preferred converted to common, shares	339,591	(134,109,750)
Common shares issued to settle payable				11,249			11,249
Common shares issued to settle payable, shares	937
Ending balance, value at Sep. 30, 2021	$ 136	$ 8		8,637,029		(25,025,235)	(16,388,032)
Ending balance, shares at Sep. 30, 2021	1,361,980	30,081,000
Beginning balance, value at Dec. 31, 2020	$ 83	$ 29		3,577,875		(8,099,627)	(4,521,640)
Beginning balance, shares at Dec. 31, 2020	832,500	164,402,750
Common shares issued for services	$ 2			540,134			540,136
Common shares issued for services, shares	21,787
Common shares issued for intangible assets	$ 3			1,424,997			1,425,000
Common shares issued for intangible assets, shares	31,250
Warrants issued with notes payable				9,533			9,533
Warrants issued for services				485,487			485,487
Series C deemed dividend					[1]	(13,477,055)	(13,477,055)
Net loss						(5,340,354)	(5,340,354)
Common stock issued for conversion of Preferred stock Series A	$ 34		[1]	1,564,217			1,564,251
Common stock issued for conversion of Preferred stock Series A, shares	339,592	(134,109,750)
Common stock issued for conversion of Preferred stock Series B	$ 7	$ (21)		14			0
Common stock issued for conversion of Preferred stock Series B, shares	70,667	(212,000)
Common shares issued for cash	$ 7			1,572,993			1,573,000
Common shares issued for cash, shares	68,802
Shares issued to convert debt	$ 3			656,247			656,250
Shares issued to convert debt, shares	27,344
Common shares issued for warrant exercise	$ 3			524,997			525,000
Common shares issued for warrant exercise, shares	26,250
Shares issued to settle payables				11,250			11,250
Shares issued to settle payables, shares	937
Common shares issued to settle debt	$ 1			179,999			180,000
Common shares issued to settle debt, shares	5,000
Shares issued to settle liability issue shares				7,400			7,400
Shares issued to settle liability issue shares, shares	2,500
Ending balance, value at Dec. 31, 2021	$ 143	$ 8		10,555,143		(26,917,036)	(16,361,742)
Ending balance, shares at Dec. 31, 2021	1,426,629	30,081,000
Beginning balance, value at Sep. 30, 2021	$ 136	$ 8		8,637,029		(25,025,235)	$ (16,388,032)
Beginning balance, shares at Sep. 30, 2021	1,361,980	30,081,000
Common shares issued for services, shares	500						500
Common shares issued for cash, shares	32,898						32,898
Ending balance, value at Dec. 31, 2021	$ 143	$ 8		10,555,143		(26,917,036)	$ (16,361,742)
Ending balance, shares at Dec. 31, 2021	1,426,629	30,081,000
Common shares issued for services				51,750			51,750
Common shares issued for services, shares	2,500
Warrants issued with notes payable				928,857			928,857
Warrants issued for services				12,976			12,976
Net loss						(4,102,134)	(4,102,134)
Option issued for services				373,704			373,704
Deemed dividend						(22,178)	(22,178)
Ending balance, value at Sep. 30, 2022	$ 143	$ 8		$ 11,922,430		$ (31,041,348)	$ (19,118,767)
Ending balance, shares at Sep. 30, 2022	1,429,129	30,081,000
[1]Series A and Series C Preferred Stock amounts reflected in mezzanine equity

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,102,134)	$ (4,404,418)	$ (5,340,354)	$ (4,670,255)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,967	4,755	6,744	5,301
Share based compensation	491,641	2,913,676	2,889,567	4,302,978
Amortization of warrant discount			2,545	11,495
Amortization of original issue discount	83,333	122,129	122,129	19,121
Amortization of debt discount	596,922	52,593
Loss on settlement of debt		149,350	149,350
Impairment of long-lived assets		15,000	16,958	32,136
Changes in operating assets and liabilities
(Increase) in stock subscription receivable			(25,000)
Decrease in other receivables	25,000	70,000
Increase in prepaid expenses	(18,285)	(86,010)	(18,294)
Increase in accrued interest		1,950
Increase (decrease) in accounts payable and accrued liabilities	1,246,170	136,712	592,320	109,131
Net cash used in operating activities	(1,671,386)	(1,024,263)	(1,604,035)	(190,093)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of intangible assets	(76,905)	(14,500)	(6,834)
Purchase of intangible assets			(14,500)	(34,300)
Net cash used in investing activities	(76,905)	(14,500)	(21,334)	(34,300)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received for issuance of common stock		1,025,000	1,573,000
Cash received upon warrant exercise		525,000	525,000
Cash received from convertible note payable	869,972		70,000
Cash paid for deferred offering costs	(16,485)		(92,975)
Advances from related party				48,083
Repayments of related party notes payable		(50,000)		(48,083)
Payments on related party notes payable			(50,000)
Cash received from related party notes payable				20,000
Cash received from third party notes payable	311,877	110,000	110,000	365,000
Repayments of not payable	(86,700)
Net cash provided by financing activities	1,078,664	1,610,000	2,135,025	385,000
Net (decrease) increase in cash	(669,627)	571,237	509,656	160,607
CASH, beginning of period	670,263	160,607	160,607
CASH, end of period	636	731,844	670,263	160,607
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid in cash	50,977	10,000	10,000
Income taxes paid in cash
Non-cash financing activities:
Common shares issued for intangible assets			1,425,000	106,000
Amortization of noncash prepaid expenses		1,930,877
Warrants issued in conjunction with debt	928,857
Deferred offering costs in accounts payable	238,448
Common shares issued upon conversion of debt			656,250
Common shares issued upon conversion of preferred stock			1,564,251
Warrants issued as debt discount			9,533	54,555
Series C preferred stock deemed dividend	$ 22,178	$ 12,521,190	13,477,055	4,440
Common shares issued to settle liabilities			$ 198,650

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.	NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation On September 26, 2022, the Company effected a 1-for-400 reverse stock split of its common stock and adjusted the ratio at which the Company’s preferred stock is convertible into common. This also impacts the number of stock options and warrants and their respective exercise prices. All common shares, stock options, warrants, and per share information presented in the accompanying condensed financial statements and notes have been adjusted, where applicable, to reflect the reverse split on a retroactive basis for all periods presented. There was no change in the par value of the Company’s common stock ( b) Use of Estimates (c) Cash and equivalents no (d) Prepaid expenses (e) Property and equipment Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) (f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. (g) Impairment of Long-Lived Assets (h) Financial Instruments and Fair Value Measurements ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (j) Revenue Recognition (k) Stock based compensation (l) Income Taxes (m) Net loss per share .	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation On September 26, 2022, the Company effected a 1-for-400 reverse stock split b) Use of Estimates (c) Cash and equivalents (d) Prepaid expenses (e) Property and equipment (f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. (g) Impairment of Long-Lived Assets Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions (j) Revenue Recognition (k) Stock based compensation Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes (m) Net income (loss) per share no . (n) Recent Accounting Pronouncements

LIQUIDITY AND GOING CONCERN CON

LIQUIDITY AND GOING CONCERN CONSIDERATIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN CONSIDERATIONS	NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying interim condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $ 4.1 31.0 3.0 Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)	NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $ 5.3 26.9

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS During the 4 th (a) MABT Covid-19 license 31,250 1,425,000 During the 4 th (b) Website 22,500 3 5,625 ( c) Patent rights option 1,800 The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $ 50,000 1,000 1,000 (d) IMT504 Patent license 6.5 The total cost for this license is 50,000 17,500 91,000 16,250 16,250 A principal goal of this license is to obtain a Priority Review Voucher (PRV) issued by the US FDA, and subsequently sell the PRV to a major pharmaceutical company. The Company and MABT will split the proceeds from the sale of such PRV equally. (e) National Institute of Health (NIH) Patent license #1 Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 4 - INTANGIBLE ASSETS, continued This license calls for the payment of a non-creditable non-refundable license issue royalty of $ 10,000 (f) National Institute of Health (NIH) Patent license #2 This license requires two separate royalty streams of payments. First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $ 8,500 (f) National Institute of Health (NIH) Patent license #2 Second is an ongoing royalty schedule: an initial royalty of $ 5,000 The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of $ 45,000	NOTE 4 - INTANGIBLE ASSETS During the 4 th (a) MABT Covid-19 license 31,250 1,425,000 During the 4 th (b) Website 22,500 , one-half in cash and one-half in common stock of the Company. The Company is amortizing this cost over 3 years. This website was placed into service in March 2021. Amortization expense for the year ended December 31, 2021 was $ 6,250 . In March 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $ 15,000 3,750 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued ( c) Patent rights option 1,800 The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $ 50,000 1,000 (d) IMT504 Patent license 6.5 The total cost for this license is 50,000 1 - 17,500 91,000 ), 2 - 16,250 3 - 16,250 (e) National Institute of Health (NIH) Patent license #1 This license calls for the payment of a non-creditable non-refundable license issue royalty of $ 10,000 (f) National Institute of Health (NIH) Patent license #2 This license requires two separate royalty streams of payments: First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $ 8,500 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued (f) National Institute of Health (NIH) Patent license #2 Second is an ongoing royalty schedule: an initial royalty of $ 5,000 The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $ 45,000 The patent rights and patent licenses are under development, therefore amortization of the costs has not commenced, as these patent rights and licenses have not been placed in service.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction. During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $ 40,000 10,000	NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arm’s length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arm’s length transaction. During 2020, one officer advanced $ 48,083 During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $ 40,000 10,000

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Notes Payable
NOTES PAYABLE	NOTE 6 - NOTES PAYABLE During the second quarter of 2022, the Company issued a promissory note in exchange for $ 200,000 This note carries a 12 During the quarter ended March 31, 2022, the Company entered into a financing for the purchase of a Directors and Officers (D&O) Liability Insurance policy. This financing carries a 5.65 zero During the second quarter of 2021, the then remaining two notes, totaling $ 40,000 10,000 During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of $ 24.00 27,343 656,250 Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)	NOTE 6 - NOTES PAYABLE During the first quarter 2021, 13 of the 15 total notes were converted into 27,343 In January 2021, the amounts receivable for notes payable were received. During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of $ 137,500 25 110,000 six months 25 The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee 2,750 9,533 9.24 During 2020, the Company issued thirteen (13) notes payable with a face amount of $ 568,750 , including 25 % OID, for a total amount of cash received of $ 455,000 . The notes are identical and carry a six-month maturity. The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee . In connection with the notes, the Company issued warrants to purchase 11,375 shares of common stock of the Company, which were recorded as a discount in the amount of $ 54,555 , which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24 % of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral. During the first quarter of 2021, 13 of the 15 note holders converted their notes into shares of common stock at the rate of $ 24.00 per share, for a total of 27,343 shares of common stock for a total of $ 656,250 convertible debt. Curative Biotechnology, Inc Notes to Financial Statements

CONVERTIBLE SENIOR SECURED NOTE

CONVERTIBLE SENIOR SECURED NOTE PAYABLE	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE SENIOR SECURED NOTE PAYABLE	NOTE 7 - CONVERTIBLE SENIOR SECURED NOTE PAYABLE During the first quarter of 2021, the Company entered into 2 notes payable for a total amount of cash received of $ 110,000 25 1 2.64 In March 2022, the Company issued a 12-month Senior Secured Note with a face amount of $ 1,142,857 12.5 12.5 869,972 142,857 125,714 Beginning in September 2022, the Company was required to make monthly redemptions at the rate of 110 179,592 125 1,428,571 The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five year warrants to purchase 57,142 0.0001 0.9 The Note is secured by all the tangible and intangible assets of the Company. In August 2022, the Company and the lender agreed to a modification of the Note. In exchange for a one month extension to begin the principal payments under this Note, the parties agreed to reduce the qualified offering amount from $ 10 7.2 4,761 58,884 Subsequent to September 30, 2022, certain of the terms of the Note were modified. See Subsequent Events.	NOTE 7 - CONVERTIBLE NOTE PAYABLE CONVERTIBLE SENIOR SECURED NOTE PAYABLE In April 2013, the Company entered into a convertible note in the principal amount of $ 97,500 4 90 0.40 128,700 100,000 5,000

LIABILITY TO ISSUE COMMON STOCK

LIABILITY TO ISSUE COMMON STOCK	12 Months Ended
	Dec. 31, 2021
Liability To Issue Common Stock
LIABILITY TO ISSUE COMMON STOCK	NOTE 8 - LIABILITY TO ISSUE COMMON STOCK In March 2020, the Company entered into an agreement to issue 2,500 7,400

DEFICIENCY IN STOCKHOLDERS EQUI

DEFICIENCY IN STOCKHOLDERS EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity [Abstract]
DEFICIENCY IN STOCKHOLDERS EQUITY	NOTE 8 – DEFICIENCY IN STOCKHOLDERS EQUITY At September 30, 2022 and December 31, 2021, the Company has 1,100,000,000 0.0001 1,429,129 1,426,629 200,000,000 0.0001 Curative Biotechnology, Inc. Notes to Condensed Financial Statements (Unaudited) NOTE 8 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued The Series A and Series C preferred stock has been accounted for in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision by the holder and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2021 134,109,750 $ 13,411 293,000 $ 29 30,000,000 $ 3,000 164,402,750 $ 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - - 81,000 8 30,000,000 $ 3,000 30,081,000 3,008 Beginning balance, value - - 81,000 8 30,000,000 $ 3,000 30,081,000 3,008 no transactions - - - - - - - - September 30, 2022 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending balance, value - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; 35 45 5,000,000 339,591 Series B Preferred are convertible in common shares of common stock at a conversion price of $ 3.00 125 203,000 67,666 Series C Preferred are convertible into at the record date; is convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry one vote for each common share that the Series C is convertible into at the record date. Quarter ended March 31, 2022: The Company issued 2,500 51,750 Quarter ended December 31, 2021: The Company issued 32,898 64,788 523,000 25,000 500 21,960 31,250 1,425,000 Quarter ended September 30, 2021: The Company issued 10,902 10,590 425,000 625 22,500 150 150 150 175 750 36,720 625 28,475 5,000 180,000 9,000 3,000 Curative Biotechnology, Inc. Notes to Condensed Financial Statements (Unaudited) NOTE 8 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued Quarter ended June 30, 2021: The Company issued 25,000 12,500 600,000 May 2026 44.00 2,500 Quarter ended March 31, 2021: The Company issued 312 5,575 17.84 937 11,250 339,591 203,000 67,666 24.00 27,343 656,250 26,250 525,000 26,250 16,250 16,250 325,000	NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY At December 31, 2021 and 2020, the Company has 1,100,000,000 0.0001 1,426,629 832,500 200,000,000 0.0001 The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) no transactions no transactions, shares December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date 35 45 5,000,000 Series B Preferred are convertible in common shares of common stock at a conversion price of $ 3.00 125 Series C Preferred are convertible into common stock aggregating 30 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the fourth quarter 2021, the Company issued 32,898 64,788 523,000 25,000 500 21,960 31,250 1,425,000 During the third quarter 2021, the Company issued 10,902 10,590 425,000 625 22,500 150 150 150 175 750 36,720 625 28,475 5,000 180,000 9,000 3,000 During the second quarter 2021, the Company issued 25,000 12,500 600,000 May 2026 44.00 2,500 During the second quarter 2021, the Company issued 625 150 150 150 175 2,100 525 525 525 525 2,100 During the first quarter 2021, the Company issued 312 5,575 17.84 937 11,250 339,591 203,000 67,666 24.00 27,343 656,250 26,250 525,000 26,250 16,250 16,250 325,000 During the 4 th 4,250 36,800 8.64 th 21,250 106,000 5.00 During the 4 th 100,000,000 1,560,840 0.0156 th 30,000,000 4,562,062 0.152 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period. During the 2nd quarter 2020, the Company issued 3,125 23,300 7.46 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the 1st quarter 2020, the Company issued 3,750 15,000 4.00 A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was $ 13,477,055 4,440

WARRANTS

WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Warrants
WARRANTS	NOTE 9 - WARRANTS Quarter ended March 31, 2022: The lender of the Convertible Senior Secured Note received five year warrants to purchase 57,142 0.0001 0.9 Quarter ended September 30, 2022: In August 2022, the Company and the lender agreed to a modification of the Note described in previous paragraph, which resulted in the lender receiving 4,761 Quarter ended December 31, 2021: The Company issued 1,008 1,008 December 2024 44.00 63,780 31,890 December 2024 36.00 60.00 Quarter ended September 30, 2021: The Company issued 10,590 10,902 60.00 56.00 2,500 49.60 34,382 Quarter ended June 30, 2021: The Company issued 12,500 25,000 May 2026 44.00 12,500 80.00 87,249 7,500 155,717 2,500 40.00 51,906 625 Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 9 – WARRANTS, continued Quarter ended March 31, 2021: The Company issued 26,250 525,000 26,250 16,250 325,000 16,250 2,750 100 20.00 9,533 12,500 20.00 40,600 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years 16.00 40.00 60.51 31.56 0.0001 80.00 0.09 0.83	NOTE 10 - WARRANTS During the fourth quarter 2021, the Company issued 1,008 1,008 December 2024 44.00 63,780 31,890 December 2024 36.00 60.00 During the third quarter 2021, the Company issued 10,590 10,902 60.00 56.00 2,500 July 2024 49.60 34,382 During the second quarter 2021, the Company issued 12,500 25,000 May 2026 44.00 12,500 80.00 87,249 7,500 40.00 155,717 During the second quarter 2021, the Company issued 2,500 40.00 51,906 625 During the first quarter 2021, the Company issued 26,250 525,000 26,250 16,250 325,000 16,250 In the first quarter 2021, the Company issued 2,750 warrants for the purchase of common stock of the Company in conjunction with the short-term debt at the rate of 2.5 warrants for each $100 loaned. These warrants carry an expiration of thirty-six months from issuance; an exercise price of $ 20.00 per share and are exercisable immediately. The warrants were recorded at a total value of $ 9,533 . In the first quarter 2021, the Company issued 12,500 20.00 40,600 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years 16.00 40.00 60.51 31.56 20.00 80.00 0.09 0.83 Curative Biotechnology, Inc Notes to Financial Statements NOTE 10 - WARRANTS, continued During the 4 th 11,375 warrants for the purchase of common stock of the Company in conjunction with the issuance of short-term debt at the rate of 2.5 warrants for each $100 loaned . These warrants carry an expiration of thirty-six months from issuance; an exercise price of $ 20.00 per share and are exercisable immediately. These warrants were valued at $ 54,555 , and are being amortized to the maturity of the related debt. During the 4 th 16,875 20.00 44,135 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life three years 12.00 109.96 30.22 20.00 0.08 0.11

OPTIONS

OPTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
OPTIONS	NOTE 10 - OPTIONS Quarter ended March 31, 2022: The Company issued 18,641 155,250 20.70 five Quarter ended September 30, 2021: The Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1 20,202 5 44.00 436,908 50 50 218,000 The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years 45.60 35.13 44.00 1.47	NOTE 11 - OPTIONS In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1 20,202 5 44.00 436,908 50 50% The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years ; stock price $ 45.60 ; volatility 35.13 ; exercise price $ 44.00 and bond equivalent yield rate 1.47 %.

EQUITY INCENTIVE PLAN

EQUITY INCENTIVE PLAN	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity Incentive Plan
EQUITY INCENTIVE PLAN	NOTE 11 - EQUITY INCENTIVE PLAN On August 26, 2021, the Company adopted a equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator. During the quarter ended March 31, 2022, a total of 2,500 18,641 20.70 five years 8.32 The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS Risk-free interest rate 1.55 % Exercise price $ 20.70 Expected life 5 Expected volatility 44.12 % Expected dividends - The Company recognized equity incentive expense of approximately $ 207,000 As of September 30, 2022, there were 18,641 20.70 A summary of the Company’s stock option plan and changes during the nine months ended September 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted average exercise price Balance - beginning of the year - $ - Granted 18,641 20.70 Exercised - - Cancelled - - Balance - end of period 18,641 $ 20.70 The aggregate intrinsic value of vested share options (the market value less the exercise price) at September 30, 2022 was zero	NOTE 11 - EQUITY INCENTIVE PLAN On August 26, 2021, the Company adopted a equity incentive plan providing for the issuance of shares of common stock, options or SARs with a rolling maximum number equal to 10% of the issued and outstanding Common Shares set at the beginning of each fiscal year. The Company may grant incentives to its directors, officers, employees and service providers. The options are exercisable for a maximum of up to ten years from the date of grant and may be subject to vesting provisions as set by the Plan Administrator. During the quarter ended March 31, 2022, a total of 2,500 18,641 20.70 five years 8.32 The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS Risk-free interest rate 1.55 % Exercise price $ 20.70 Expected life 5 Expected volatility 44.12 % Expected dividends - The Company recognized a equity incentive expense of $ 243,435 As of June 30, 2022, there were 18,641 20.70 no A summary of the Company’s stock option plan and changes during the six months ended June 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted average exercise price Balance - beginning of the year - $ - Granted 18,641 20.70 Exercised - - Cancelled - - Balance - end of period 18,641 $ 20.70 The aggregate intrinsic value of vested share options (the market value less the exercise price) at June 30, 2022 was zero

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 12 - FINANCIAL INSTRUMENTS (a) Liquidity Risk (b) Interest Rate Risk Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)	NOTE 12 - FINANCIAL INSTRUMENTS (a) Liquidity Risk (b) Interest Rate Risk

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2021
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements

IMPAIRMENT OF LONG LIVED ASSETS

IMPAIRMENT OF LONG LIVED ASSETS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
IMPAIRMENT OF LONG LIVED ASSETS	NOTE 13 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter 2021 the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $ 1,958 In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s legacy website was written off, for a total charge of $ 15,000	NOTE 14 - IMPAIRMENT OF LONG-LIVED ASSETS NOTE 12 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $ 1,958 In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s old website was written off, for a total of $ 15,000 During the 4 th 34,516

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 15 - INCOME TAXES The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ - The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 % The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ - Curative Biotechnology, Inc Notes to Financial Statements NOTE 15 - INCOME TAXES, continued The change in valuation allowance was ($ 1,158,381 1,021,331 100 The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 - COMMITMENTS AND CONTINGENCIES (a) Other	NOTE 16 - COMMITMENTS AND CONTINGENCIES (a) Other

CONCENTRATIONS OF CREDIT RISK

CONCENTRATIONS OF CREDIT RISK	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS OF CREDIT RISK	NOTE 15 - CONCENTRATIONS OF CREDIT RISK (a) Cash zero 416,178	NOTE 17 - CONCENTRATIONS OF CREDIT RISK (a) Cash 416,178 no

COVID-19 PANDEMIC AND VARIANTS

COVID-19 PANDEMIC AND VARIANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]
COVID-19 PANDEMIC AND VARIANTS	NOTE 16 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.	NOTE 18 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 - SUBSEQUENT EVENTS (a) Convertible Senior Secured Note Payable and Warrants 4,761 66,666 60,000 On November 16, 2022, the parties to this convertible note agreed to another amendment, which further delayed the first principal payment until December 17, 2022. The Company also amended the warrant to increase the number of shares of common stock underlying the warrant by another 4,762 71,428 On December 16, 2022, the parties to this convertible note agreed to another amendment, which further delayed the first principal payment until January 17, 2023. The Company also amended the warrant to increase the number of shares of common stock underlying the warrant by another 4,762 76,190 In December 2022, the Company sold 116,000 116,000 19,048 152,390	NOTE 19 - SUBSEQUENT EVENTS (a) Intangible Assets (b) Senior Secured Note 1,142,857 , with a stated 12.5 % original issue discount (OID). The Note carries a 12.5% The Company received $ 874,286 in cash, net of the OID of $ 142,857 and legal and other fees in the amount of $ 125,714 . The Note was issued to Puritan Partners, LLC, an institutional investor. Beginning in September 2022, the Company is required to make monthly redemptions at the rate of 110 179,592 125% 1,428,571 The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five-year warrants to purchase 57,142 shares of common stock of the Company, with an exercise price of $ 0.0001 per share. These warrants were recorded as debt discount in the amount of $ 1.0 million which will be amortized over the term of the Note. The warrants can be exercised on a cash-less basis if a registration statement for the common shares underlying the warrants is not declared effective by September 2022. The Note is secured by all the tangible and intangible assets of the Company. (c) Deficiency in Stockholders Equity 2,500 51,750 In January 2022, the $ 25,000 (d) Options 18,663 five 20.70 155,250 (e) Reverse Stock Split

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation On September 26, 2022, the Company effected a 1-for-400 reverse stock split of its common stock and adjusted the ratio at which the Company’s preferred stock is convertible into common. This also impacts the number of stock options and warrants and their respective exercise prices. All common shares, stock options, warrants, and per share information presented in the accompanying condensed financial statements and notes have been adjusted, where applicable, to reflect the reverse split on a retroactive basis for all periods presented. There was no change in the par value of the Company’s common stock	a) Basis of Presentation On September 26, 2022, the Company effected a 1-for-400 reverse stock split
Use of Estimates	( b) Use of Estimates	b) Use of Estimates
Cash and equivalents	(c) Cash and equivalents no	(c) Cash and equivalents
Prepaid expenses	(d) Prepaid expenses	(d) Prepaid expenses
Property and equipment	(e) Property and equipment Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited)	(e) Property and equipment
Intangible Assets	(f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.	(f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.
Impairment of Long-Lived Assets	(g) Impairment of Long-Lived Assets	(g) Impairment of Long-Lived Assets
Financial Instruments and Fair Value Measurements	(h) Financial Instruments and Fair Value Measurements ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.	(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Related Party Transactions	(i) Related Party Transactions Curative Biotechnology, Inc Notes to Condensed Financial Statements (Unaudited) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued	(i) Related Party Transactions
Revenue Recognition	(j) Revenue Recognition	(j) Revenue Recognition
Stock based compensation	(k) Stock based compensation	(k) Stock based compensation
Income Taxes	(l) Income Taxes	(l) Income Taxes
Net loss per share	(m) Net loss per share .	(m) Net income (loss) per share no .
Recent Accounting Pronouncements		(n) Recent Accounting Pronouncements

DEFICIENCY IN STOCKHOLDERS EQ_2

DEFICIENCY IN STOCKHOLDERS EQUITY (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF STOCKHOLDERS EQUITY	The Series A and Series C preferred stock has been accounted for in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision by the holder and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2021 134,109,750 $ 13,411 293,000 $ 29 30,000,000 $ 3,000 164,402,750 $ 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - - 81,000 8 30,000,000 $ 3,000 30,081,000 3,008 Beginning balance, value - - 81,000 8 30,000,000 $ 3,000 30,081,000 3,008 no transactions - - - - - - - - September 30, 2022 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending balance, value - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008	The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) no transactions no transactions, shares December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008

EQUITY INCENTIVE PLAN (Tables)

EQUITY INCENTIVE PLAN (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity Incentive Plan
SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS	Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS Risk-free interest rate 1.55 % Exercise price $ 20.70 Expected life 5 Expected volatility 44.12 % Expected dividends -	Assumptions used in the pricing model are as provided below. SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS Risk-free interest rate 1.55 % Exercise price $ 20.70 Expected life 5 Expected volatility 44.12 % Expected dividends -
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of the Company’s stock option plan and changes during the nine months ended September 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted average exercise price Balance - beginning of the year - $ - Granted 18,641 20.70 Exercised - - Cancelled - - Balance - end of period 18,641 $ 20.70	A summary of the Company’s stock option plan and changes during the six months ended June 30, 2022 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted average exercise price Balance - beginning of the year - $ - Granted 18,641 20.70 Exercised - - Cancelled - - Balance - end of period 18,641 $ 20.70

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
General And Administrative Expenses
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE	SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE	The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ -
SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE	The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ -

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		12 Months Ended
	Sep. 26, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022
Accounting Policies [Abstract]
Reverse stock split	1-for-400 reverse stock split
Dilutive shares of common stock equivalents		0	0
Cash equivalents		$ 0		$ 0

LIQUIDITY AND GOING CONCERN C_2

LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income loss	$ 1,418,430	$ 1,015,654	$ 4,102,134	$ 4,404,418	$ 5,340,354	$ 4,670,255
Accumulated deficit	31,041,348		31,041,348		$ 26,917,036	$ 8,099,627
Working capital	$ 3,000,000		$ 3,000,000

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Apr. 30, 2022

Sep. 30, 2021

Jan. 31, 2021

Dec. 31, 2020

Oct. 31, 2020

Mar. 31, 2020

Dec. 31, 2021

Mar. 31, 2021

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2022

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Finite-Lived Intangible Assets [Line Items]

Purchase of assets,value

$ 1,425,000

$ 106,000

Number of value, service

$ 23,300

$ 15,000

$ 51,750

$ 518,177

540,136

36,800

Common stock issued for services, shares

500

16,250

3,125

3,750

Payments to acquire intangible assets

14,500

$ 34,300

Website [Member]

Finite-Lived Intangible Assets [Line Items]

Number of value, service

$ 22,500

$ 15,000

Intangible assets remaining amortization period

3 years

Amortization of intangible assets

$ 5,625

$ 6,250

Common stock issued for services, shares

3,750

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Research and development arrangement, description

The total cost for this license is 50,000 shares of the Company’s common stock, issuable in three tranches -

Patents [Member] | Investigational New Drug [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

50,000

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

17,500

Purchase of assets,value

$ 91,000

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

17,500

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

16,250

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

16,250

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

16,250

Patents [Member] | Investigational New Drug [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

16,250

National Institute of Health Patent License One [Member]

Finite-Lived Intangible Assets [Line Items]

Payments for royalties

$ 10,000

National Institute of Health Patent License Two [Member] | Royalty [Member]

Finite-Lived Intangible Assets [Line Items]

Royalty expense

$ 8,500

National Institute of Health Patent License Two [Member] | Royalty One [Member]

Finite-Lived Intangible Assets [Line Items]

Intangible assets ability renew or extend arrangement

The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty

The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

Payments for royalties

$ 45,000

Royalty expense

$ 5,000

Mid-Atlantic BioTheraputics, Inc [Member]

Finite-Lived Intangible Assets [Line Items]

Purchase of assets, shares

31,250

Purchase of assets,value

$ 1,425,000

Mid-Atlantic BioTheraputics, Inc [Member] | Patents [Member]

Finite-Lived Intangible Assets [Line Items]

License development

6,500,000

IEM, Inc [Member] | Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Cost of option

$ 1,800

Intangible assets ability renew or extend arrangement

The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000

Payments to acquire intangible assets

$ 50,000

Intangible assets cost incurred to renew or extend, value

$ 1,000

$ 1,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Jun. 30, 2021
Related Party Transaction [Line Items]
Advances from related party		$ 48,083
Officer [Member] | Two Notes [Member]
Related Party Transaction [Line Items]
Principal amount			$ 40,000	$ 40,000
Unamortized discount			$ 10,000	$ 10,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Proceeds from notes payable			$ 869,972		$ 70,000
Purchase of common stock warrants				10,590	64,788			12,500
Share price				$ 45.60
Directors and Officers [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage							5.65%
Notes payable	$ 0		$ 0
Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Issued and outstanding common stock shares, percentage		2.64%
13 Notes [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument shares issued		27,343
Two Notes Payable [Member]
Short-Term Debt [Line Items]
Principal amount		$ 137,500
Original issue discount, percentage		25%
Proceeds from notes payable		$ 110,000
Maturity term		6 months
Maturity extension description		The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee
Purchase of common stock warrants		2,750
Unamortized discount		$ 9,533
Two Notes Payable [Member] | Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Issued and outstanding common stock shares, percentage		9.24%
13 Notes Payable [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument shares issued		27,343
Principal amount						$ 568,750
Original issue discount, percentage						25%
Proceeds from notes payable						$ 455,000
Maturity term						6 months
Maturity extension description						The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee
Purchase of common stock warrants						11,375
Unamortized discount						$ 54,555
Share price		$ 24
Debt conversion converted instrument amount		$ 656,250
13 Notes Payable [Member] | Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Issued and outstanding common stock shares, percentage						9.24%
Promissory Note Exchange [Member]
Short-Term Debt [Line Items]
Proceeds from notes payable	$ 200,000
Short term debt terms			This note carries a 12% interest rate, interest payable monthly, and a six month maturity
Debt instrument stated percentage	12%		12%
Two Notes [Member] | Officer [Member]
Short-Term Debt [Line Items]
Principal amount				$ 40,000				$ 40,000
Unamortized discount				$ 10,000				$ 10,000

CONVERTIBLE SENIOR SECURED NO_2

CONVERTIBLE SENIOR SECURED NOTE PAYABLE (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended					9 Months Ended		12 Months Ended
	Aug. 31, 2022	Apr. 30, 2013	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Short-Term Debt [Line Items]
Issuance of common stock, shares				32,898	10,902	25,000		21,250
Proceeds from notes payable									$ 869,972		$ 70,000
Class of warrant exercise price per share				$ 44		$ 44					$ 44
Number of warrants				64,788	10,590	12,500				10,590	64,788
Maximum [Member]
Short-Term Debt [Line Items]
Class of warrant exercise price per share				$ 60	$ 56	$ 40	$ 20			$ 56	$ 60
Minimum [Member]
Short-Term Debt [Line Items]
Class of warrant exercise price per share				$ 36	$ 60	$ 80				$ 60	$ 36
Beginning in September 2022 [Member]
Short-Term Debt [Line Items]
Debt interest rate									125%
Debt discount amount									$ 900,000
Debt instrument redemption percentage									110%
Debt conversion, original debt, amount									$ 179,592
Debt redemption amount									$ 1,428,571
Number of warrant shares									57,142
Class of warrant exercise price per share									$ 0.0001
Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Debt conversion price percentage											30%
Issued outstanding shares percentage							2.64%
Two Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount reduce							$ 137,500
Proceeds from notes payable							$ 110,000
Debt interest rate							25%
Debt discount amount							$ 9,533
Number of warrants							2,750
Two Notes Payable [Member] | Series C Preferred Stock [Member]
Short-Term Debt [Line Items]
Warrant loaned							$ 1
Issued outstanding shares percentage							9.24%
12-month Senior Secured Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount reduce			$ 1,142,857
Debt interest rate			12.50%
Debt instrument original interest rate			12.50%
Proceeds from convertible debt			$ 869,972
Debt discount amount			142,857
Legal fees			$ 125,714
Convertible Senior Secured Note Payable and Warrants [Member] | Lender [Member]
Short-Term Debt [Line Items]
Number of warrants	4,761
Fair value of warrant	$ 58,884
Convertible Senior Secured Note Payable and Warrants [Member] | Lender [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount reduce	10,000,000
Convertible Senior Secured Note Payable and Warrants [Member] | Lender [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount reduce	$ 7,200,000
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount reduce		$ 97,500
Debt instrument interest rate		4%
Debt conversion price percentage		90%
Debt instrument conversion price per share		$ 0.40
Accrued interest												$ 128,700
Debt payment amount											$ 100,000
Issuance of common stock, shares											5,000

LIABILITY TO ISSUE COMMON STO_2

LIABILITY TO ISSUE COMMON STOCK (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2020	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Issuance of common stock for services, shares		500	16,250	3,125	3,750
Issuance of common stock for services, value				$ 23,300	$ 15,000	$ 51,750	$ 518,177	$ 540,136	$ 36,800
Common Stock [Member]
Issuance of common stock for services, shares	2,500	500				2,500	21,288	21,787	4,250
Issuance of common stock for services, value	$ 7,400						$ 2	$ 2

SCHEDULE OF STOCKHOLDERS EQUITY

SCHEDULE OF STOCKHOLDERS EQUITY (Details) - USD ($)		3 Months Ended					9 Months Ended		12 Months Ended
		Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value		$ (16,388,032)	$ (4,521,640)			$ (88,435)	$ (16,361,742)	$ (4,521,640)	$ (4,521,640)	$ (88,435)
Common shares issued for services					$ 23,300	$ 15,000	51,750	518,177	540,136	36,800
Common shares issued for services, shares		500	16,250		3,125	3,750
Conversion to common shares									1,564,251
no transactions				$ 36,800				836,250	180,000
no transactions, shares				4,250
Ending balance, value		$ (16,361,742)		$ (4,521,640)			(19,118,767)	(16,388,032)	(16,361,742)	(4,521,640)
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares issued for services				$ 1,560,840
Common shares issued for services, shares				100,000,000
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares issued for services, shares			16,250
Conversion to common shares			$ 656,250
Conversion to common shares, shares			27,343
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
no transactions				$ 4,562,062
no transactions, shares				30,000,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value		$ 8	$ 29			$ 29	$ 8	$ 29	$ 29	$ 29
Beginning balance, shares		30,081,000	164,402,750			34,402,750	30,081,000	164,402,750	164,402,750	34,402,750
Common shares issued for services
Conversion to common shares	[1]
Conversion to common shares, shares									(134,109,750)
no transactions
Ending balance, value		$ 8		$ 29			$ 8	$ 8	$ 8	$ 29
Ending balance, shares		30,081,000		164,402,750			30,081,000	30,081,000	30,081,000	164,402,750
Preferred Stock [Member] | Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value			$ 13,411			$ 3,411		$ 13,411	$ 13,411	$ 3,411
Beginning balance, shares			134,109,750			34,109,750		134,109,750	134,109,750	34,109,750
Common shares issued for services										$ 10,000
Common shares issued for services, shares										100,000,000
Conversion to common shares									$ (13,411)
Conversion to common shares, shares									(134,109,750)
no transactions
no transactions, shares
Ending balance, value				$ 13,411						$ 13,411
Ending balance, shares				134,109,750						134,109,750
Preferred Stock [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value			$ 29			$ 29	$ 8	$ 29	$ 29	$ 29
Beginning balance, shares			293,000			293,000	81,000	293,000	293,000	293,000
Common shares issued for services
Common shares issued for services, shares
Conversion to common shares									$ (21)
Conversion to common shares, shares									(212,000)
no transactions
no transactions, shares
Ending balance, value		$ 8		$ 29			$ 8		$ 8	$ 29
Ending balance, shares		81,000		293,000			81,000		81,000	293,000
Preferred Stock [Member] | Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value			$ 3,000				$ 3,000	$ 3,000	$ 3,000
Beginning balance, shares			30,000,000				30,000,000	30,000,000	30,000,000
Common shares issued for services										$ 3,000
Common shares issued for services, shares										30,000,000
Conversion to common shares
Conversion to common shares, shares
no transactions
no transactions, shares
Ending balance, value		$ 3,000		$ 3,000			$ 3,000		$ 3,000	$ 3,000
Ending balance, shares		30,000,000		30,000,000			30,000,000		30,000,000	30,000,000
Preferred Stock [Member] | Series A, B and C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value			$ 16,440			$ 3,440	$ 3,008	$ 16,440	$ 16,440	$ 3,440
Beginning balance, shares			164,402,750			34,402,750	30,081,000	164,402,750	164,402,750	34,402,750
Common shares issued for services										$ 13,000
Common shares issued for services, shares										130,000,000
Conversion to common shares									$ (13,432)
Conversion to common shares, shares									(134,321,750)
no transactions
no transactions, shares
Ending balance, value		$ 3,008		$ 16,440			$ 3,008		$ 3,008	$ 16,440
Ending balance, shares		30,081,000		164,402,750			30,081,000		30,081,000	164,402,750
[1]Series A and Series C Preferred Stock amounts reflected in mezzanine equity

DEFICIENCY IN STOCKHOLDERS EQ_3

DEFICIENCY IN STOCKHOLDERS EQUITY (Details Narrative) - USD ($)			1 Months Ended										3 Months Ended								9 Months Ended		12 Months Ended
	Jan. 20, 2022	Apr. 30, 2013	Dec. 31, 2022	Aug. 31, 2022	May 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	May 31, 2021	Mar. 31, 2020	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 16, 2022	Nov. 16, 2022	Jan. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized								1,100,000,000						1,100,000,000				1,100,000,000			1,100,000,000		1,100,000,000	1,100,000,000
Common stock, par value								$ 0.0001						$ 0.0001				$ 0.0001			$ 0.0001		$ 0.0001	$ 0.0001
Common stock, shares issued								1,426,629						1,426,629				832,500			1,429,129		1,426,629	832,500
Common stock, shares outstanding								1,426,629						1,426,629				832,500			1,429,129		1,426,629	832,500
Preferred stock, shares authorized								200,000,000						200,000,000				200,000,000			200,000,000		200,000,000	200,000,000
Preferred stock, par value								$ 0.0001						$ 0.0001				$ 0.0001			$ 0.0001		$ 0.0001	$ 0.0001
Issuance of shares, value																$ 600,000		$ 106,000				$ 1,025,000	$ 1,573,000
Number of issuance, shares														32,898	10,902	25,000		21,250
Number of securities called by warrants or rights								64,788	10,590					64,788	10,590	12,500						10,590	64,788
Security deposit								$ 25,000						$ 25,000									$ 25,000
Common shares issued for services, shares														500			16,250		3,125	3,750
Common shares issued for services																			$ 23,300	$ 15,000	$ 51,750	$ 518,177	$ 540,136	$ 36,800
Number of vested shares								150	625	150	625				150	150
Maturity period														2024-12		2026-05
Share price								$ 44						$ 44		$ 44							$ 44
Number of common stock to settle liability																2,500
Shares issued price per share												$ 4						$ 8.64	$ 7.46	$ 4				$ 8.64
Number of value conversion of convertible securities																							$ 1,564,251
Exercise of warrants for services, shares																	16,250
Exchange of shares for services, shares																		4,250
Exchange of shares for services, valued																		$ 36,800				836,250	180,000
Vesting rate description																		50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period.
Deemed dividend																							$ 13,477,055	$ 4,440
Number of securities exchange warrants or rights								64,788						64,788									64,788
Mid Atlantic Bi-theraputics Inc [Member]
Class of Stock [Line Items]
Issuance of shares, value														$ 1,425,000
Number of issuance, shares														31,250
Share-Based Payment Arrangement, Employee [Member]
Class of Stock [Line Items]
Common shares issued for services, shares																2,500
Common shares issued for services													$ 51,750
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Convertible threshold percentage of stock price trigger, percentage		90%
Debt instrument convertible conversion price		$ 0.40
Number of issuance, shares																							5,000
Common shares issued for services, shares															5,000
Common shares issued for services															$ 180,000
Forecast [Member]
Class of Stock [Line Items]
Number of vested shares				175		175
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares authorized																											2,500
Number of securities called by warrants or rights																									76,190	71,428
Number of vested shares	625				625	150
Advisory Board [Member]
Class of Stock [Line Items]
Common shares issued for services, shares															625	625
Common shares issued for services															$ 22,500
Number of vested shares								150							150
Advisory Board [Member] | Forecast [Member]
Class of Stock [Line Items]
Number of vested shares				175
Advisory Board [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of vested shares						150
Board of Directors [Member]
Class of Stock [Line Items]
Common shares issued for services, shares															750
Common shares issued for services															$ 36,720
Advisory Board One [Member]
Class of Stock [Line Items]
Common shares issued for services, shares															625
Common shares issued for services															$ 28,475
Employee [Member]
Class of Stock [Line Items]
Common shares issued for services, shares																2,100
Number of vested shares								525	525
Employee [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of vested shares							525
Employees [Member]
Class of Stock [Line Items]
Number of issuance, shares													2,500
Number of vested shares																525
Two Employees [Member]
Class of Stock [Line Items]
Common shares issued for services, shares																2,100
MABT's COVID-19 Vaccine [Member]
Class of Stock [Line Items]
Issuance of shares, value														$ 1,425,000
Number of issuance, shares														31,250
Common Stock [Member]
Class of Stock [Line Items]
Issuance of shares, value															$ 425,000		$ 525,000					$ 4	$ 7
Number of issuance, shares														32,898			26,250					35,904	68,802
Number of securities called by warrants or rights							57,142	1,008	10,590				57,142	1,008	10,590		26,250	11,375				10,590	1,008	11,375
Common shares issued for services, shares												2,500		500							2,500	21,288	21,787	4,250
Common shares issued for services												$ 7,400										$ 2	$ 2
Preferred stock shares issued upon conversion																	339,591
Share price																		$ 20						$ 20
Shares issued price per share																	$ 17.84	$ 5						$ 5
Number of common stock to settled																	937
Value of common stock settled																	$ 11,250
Number of shares conversion of convertible securities																							339,592
Number of value conversion of convertible securities																							$ 34
Exchange of shares for services, shares																						32,344	5,000
Exchange of shares for services, valued																						$ 3	$ 1
Conversion of stock shares issued																	203,000
Warrants and rights outstanding							$ 900,000						$ 900,000					$ 54,555						$ 54,555
Common Stock [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Shares issued price per share																	$ 24
Number of shares conversion of convertible securities																	27,343
Number of value conversion of convertible securities																	$ 656,250
Common Stock [Member] | Exchange for Services [Member]
Class of Stock [Line Items]
Common shares issued for services, shares																	312
Common shares issued for services																	$ 5,575
Number of value, services																	$ 5,575
Common Stock [Member] | MABT's COVID-19 Vaccine [Member]
Class of Stock [Line Items]
Issuance of shares, value														$ 523,000
Common shares issued for services														21,960
Warrants to purchase of common stock														523,000
Warrant [Member]
Class of Stock [Line Items]
Issuance of shares, value														$ 25,000
Number of issuance, shares														1,008
Number of securities called by warrants or rights								63,780	2,500					63,780	2,500	2,500	2,750					2,500	63,780
Common shares issued for services																	$ 325,000
Maturity period														2024-12	2024-07
Share price									$ 49.60						$ 49.60			$ 20				$ 49.60		$ 20
Warrants and rights outstanding									$ 34,382						$ 34,382	$ 51,906	$ 9,533					$ 34,382
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock voting rights description																					Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date;		Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date
Convertible threshold percentage of stock price trigger, percentage																					35%		35%
Debt instrument redemption price percentage																					45%		45%
Issuance of shares, value																					$ 5,000,000		$ 5,000,000
Common shares issued for services, shares																		100,000,000
Common shares issued for services																		$ 1,560,840
Preferred stock shares issued upon conversion																	339,591
Shares issued price per share																		$ 0.0156						0.0156
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Debt instrument redemption price percentage																					125%		125%
Debt instrument convertible conversion price								$ 3						$ 3							$ 3		$ 3
Number of issuance, shares																	26,250
Number of securities called by warrants or rights																	26,250
Common shares issued for services, shares																	16,250
Preferred stock convertible shares issuable									9,000						9,000		203,000					9,000
Preferred stock shares issued upon conversion									3,000						3,000		67,666					3,000
Shares issued price per share																	$ 24
Number of shares conversion of convertible securities																	27,343
Number of value conversion of convertible securities																	$ 656,250
Exercise of warrants for services, shares																	16,250
Conversion of stock shares issued																	67,666
Warrants and rights outstanding																	$ 525,000
Series B Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Issuance of shares, value			$ 116,000
Number of issuance, shares			116,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Convertible threshold percentage of stock price trigger, percentage																							30%
Shares issued price per share																		$ 0.152						$ 0.152
Exchange of shares for services, shares																		30,000,000
Exchange of shares for services, valued																		$ 4,562,062
Series A Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock shares issued																	339,591

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)		1 Months Ended							3 Months Ended							6 Months Ended	9 Months Ended		12 Months Ended
	Jan. 20, 2022	May 31, 2022	Apr. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	May 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 16, 2022	Nov. 16, 2022	Mar. 31, 2022
Purchase of common stock warrants				64,788	10,590				64,788	10,590	12,500							10,590	64,788
Sale of stock number of shares issued in transaction									1,008	10,902	25,000
Warrant term									2024-12		2026-05
Warrant exercise price per share				$ 44					$ 44		$ 44								$ 44
Warrants outstanding											$ 87,249
Shares vested				150	625	150	625			150	150
Number of shares issued in cash											$ 600,000		$ 106,000					$ 1,025,000	$ 1,573,000
Exercise of warrants shares												26,250
Shares issued												16,250
Common shares issued for services														$ 23,300	$ 15,000		$ 51,750	$ 518,177	$ 540,136	$ 36,800
Common shares issued for services, shares									500			16,250		3,125	3,750
Expected term										10 years		5 years	3 years			5 years	5 years
Share price					$ 45.60					$ 45.60								$ 45.60
Expected volatility rate										35.13%						44.12%	44.12%
Exercise price					44					$ 44								44
Expected dividend rate										1.47%
Common shares issued for cash, shares									32,898	10,902	25,000		21,250
Stock issued during period shares exercise of warrants												16,250
Convertible Senior Secured Note [Member]
Warrant exercise price per share																							$ 0.0001
Two Peoples [Member]
Purchase of common stock warrants													16,875							16,875
Warrant outstanding amount													$ 44,135							$ 44,135
Share price													$ 12							$ 12
Exercise price													$ 20							$ 20
Subsequent Event [Member]
Purchase of common stock warrants																					76,190	71,428
Shares vested	625	625	150
Shares issued																					4,762	4,762
Legal Services [Member]
Purchase of common stock warrants											7,500
Warrant outstanding amount											$ 155,717
Minimum [Member]
Warrant exercise price per share				$ 36	60				$ 36	$ 60	$ 80							60	$ 36
Minimum [Member] | Two Peoples [Member]
Expected volatility rate													30.22%
Expected dividend rate													0.08%
Maximum [Member]
Warrant exercise price per share				$ 60	$ 56				$ 60	$ 56	40	$ 20						$ 56	$ 60
Maximum [Member] | Two Peoples [Member]
Expected volatility rate													109.96%
Expected dividend rate													0.11%
Maximum [Member] | Legal Services [Member]
Warrant exercise price per share											$ 40
Common Stock [Member]
Purchase of common stock warrants				1,008	10,590				1,008	10,590		26,250	11,375					10,590	1,008	11,375			57,142
Warrant exercise price per share													$ 20							$ 20
Warrant outstanding amount													$ 54,555							$ 54,555			$ 900,000
Number of shares issued in cash										$ 425,000		$ 525,000						$ 4	$ 7
Common shares issued for services								$ 7,400										$ 2	$ 2
Common shares issued for services, shares								2,500	500								2,500	21,288	21,787	4,250
Warrants description												100								the Company in conjunction with the issuance of short-term debt at the rate of 2.5 warrants for each $100 loaned
Common shares issued for cash, shares									32,898			26,250						35,904	68,802
Common Stock [Member] | Lender [Member]
Purchase of common stock warrants																	4,761
Warrant [Member]
Purchase of common stock warrants				63,780	2,500				63,780	2,500	2,500	2,750						2,500	63,780
Sale of stock number of shares issued in transaction									31,890
Warrant term									2024-12	2024-07
Warrant exercise price per share					$ 49.60					$ 49.60			$ 20					$ 49.60		$ 20
Warrant outstanding amount					$ 34,382					$ 34,382	$ 51,906	$ 9,533						$ 34,382
Number of shares issued in cash									$ 25,000
Common shares issued for services												$ 325,000
Common shares issued for cash, shares									1,008
Warrants [Member]
Purchase of common stock warrants												12,500
Warrant exercise price per share												$ 20
Warrant outstanding amount												$ 40,600
Warrants [Member] | Minimum [Member]
Share price												$ 16
Expected volatility rate												60.51%
Exercise price												$ 20
Expected dividend rate												0.09%
Warrants [Member] | Minimum [Member] | Black Scholes [Member]
Exercise price												$ 0.0001
Warrants [Member] | Maximum [Member]
Share price												$ 40
Expected volatility rate												31.56%
Exercise price												$ 80
Expected dividend rate												0.83%

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended							6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Jan. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common shares issued for cash, shares					32,898	10,902	25,000		21,250
Share price						$ 45.60						$ 45.60
Common shares issued for cash							$ 600,000		$ 106,000			$ 1,025,000	$ 1,573,000
Expected term						10 years		5 years	3 years	5 years	5 years
Expected volatility rate						35.13%				44.12%	44.12%
Exercise price						$ 44						$ 44
Expected dividend rate						1.47%
Purchase shares of common stock	18,641		18,641							18,641	18,641
Aggregate intrinsic value of vested share options	$ 0		$ 0							$ 0	$ 0
Exercise price	$ 20.70		$ 20.70							$ 20.70	$ 20.70
Equity Option [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share based compensation expense			$ 218,000								$ 218,000
Board of Advisory [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options percentage						1%
Common shares issued for cash, shares						20,202
Proceeds from offering						$ 5,000,000
Share price						$ 44						$ 44
Common shares issued for cash						$ 436,908
Options vested percentage						50%
Board of Advisory [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options vested percentage	50%
Three Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Purchase shares of common stock				18,641
Aggregate intrinsic value of vested share options				$ 155,250
Exercise price				$ 20.70
Stock option, term				5 years
Three Employees [Member] | Subsequent Event [Member] | Equity Option [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share price		$ 20.70
Stock option, term		5 years

SCHEDULE OF FAIR VALUE OF STOCK

SCHEDULE OF FAIR VALUE OF STOCK OPTION ASSUMPTIONS (Details) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Sep. 30, 2022
Equity Incentive Plan
Risk-free interest rate				1.55%	1.55%
Exercise price				$ 20.70	$ 20.70
Expected life	10 years	5 years	3 years	5 years	5 years
Expected volatility	35.13%			44.12%	44.12%
Expected dividends

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	6 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022
Equity Incentive Plan
Number of options, Beginning balance
Weighted Average Exercise Price, Beginning Balance
Number of options, Granted	18,641	18,641
Weighted Average Exercise Price, Granted	$ 20.70	$ 20.70
Number of options,Exercised
Weighted Average Exercise Price,Exercised
Number of options, Cancelled
Weighted Average Exercise Price, Cancelled
Number of options, Ending Balance	18,641	18,641
Weighted Average Exercise Price, Ending Balance	$ 20.70	$ 20.70

EQUITY INCENTIVE PLAN (Details

EQUITY INCENTIVE PLAN (Details Narrative) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Sep. 30, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common shares issued for cash, shares		32,898	10,902	25,000		21,250
Number of options, Granted							18,641	18,641
Weighted average exercise price, granted							$ 20.70	$ 20.70
Expected term			10 years		5 years	3 years	5 years	5 years
Number of options, Granted							18,641	18,641
Non-vested options outstanding							0
Aggregate intrinsic value of vested share options							$ 0	$ 0
Employees [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common shares issued for cash, shares	2,500
Number of options, Granted	18,641
Weighted average exercise price, granted	$ 20.70
Expected term	5 years
Weighted-average grant date fair value	$ 8.32
Share-based payment arrangement, expense							$ 243,435	$ 207,000

SCHEDULE OF GENERAL AND ADMINIS

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
General And Administrative Expenses
Salaries					$ 1,016,881	$ 143,065
Share based compensation			$ 491,641	$ 2,913,676	2,889,567	4,302,978
Professional fees					225,384	117,860
Other					79,523	34,399
Total general and administrative expenses	$ 622,252	$ 738,367	$ 1,777,596	$ 3,837,554	$ 4,211,355	$ 4,598,302

IMPAIRMENT OF LONG LIVED ASSE_2

IMPAIRMENT OF LONG LIVED ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Depreciation	$ 1,958
Indefinite lived intangble assets written off		$ 15,000
Impairment charge			$ 34,516

SCHEDULE OF COMPONENTS OF INCOM

SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Current
Deferred
Total tax provisions

SCHEDULE OF EFFECTIVE RECONCILI

SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. Federal statutory income tax rate	(21.00%)	(21.00%)
State income tax, net of federal benefit	(4.50%)	(4.50%)
Valuation allowance	25.50%	25.50%
Total	0%	0%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 1,337,957	$ 831,988
Stock based compensation	1,600,548	958,197
Other		(10,061)
Total	2,938,505	1,780,124
Less: valuation allowance	(2,938,505)	(1,780,124)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Deferred tax asset change in valuation allowance	$ 1,158,381	$ 1,021,331
Effective income tax rate percentage	100%

CONCENTRATIONS OF CREDIT RISK (

CONCENTRATIONS OF CREDIT RISK (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Cash, FDIC insured amount	$ 0	$ 416,178	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				1 Months Ended				3 Months Ended						9 Months Ended		12 Months Ended
	Dec. 16, 2022	Nov. 16, 2022	Oct. 14, 2022	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsequent Event [Line Items]
Purchase of common stock warrants									64,788	10,590	12,500				10,590	64,788
Class of warrant exercise price per share									$ 44		$ 44					$ 44
Common stock shares, authorized					1,100,000,000				1,100,000,000				1,100,000,000	1,100,000,000		1,100,000,000
Common stock, value					$ 143				$ 143				$ 83	$ 143		$ 143
Common stock, shares issued					1,429,129				1,426,629				832,500	1,429,129		1,426,629
Share price										$ 45.60					$ 45.60
Shares issued												16,250
Common shares issued for cash, shares									32,898	10,902	25,000		21,250
Common shares issued for cash											$ 600,000		$ 106,000		$ 1,025,000	$ 1,573,000
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Monthly redemptions														125%		125%
Purchase of common stock warrants												26,250
Common shares issued for cash, shares												26,250
Warrant [Member]
Subsequent Event [Line Items]
Purchase of common stock warrants									63,780	2,500	2,500	2,750			2,500	63,780
Class of warrant exercise price per share										$ 49.60			$ 20		$ 49.60
Common shares issued for cash, shares									1,008
Common shares issued for cash									$ 25,000
Common Stock [Member]
Subsequent Event [Line Items]
Purchase of common stock warrants						57,142		57,142	1,008	10,590		26,250	11,375		10,590	1,008
Class of warrant exercise price per share													$ 20
Common shares issued for cash, shares									32,898			26,250			35,904	68,802
Common shares issued for cash										$ 425,000		$ 525,000			$ 4	$ 7
Three Employees [Member]
Subsequent Event [Line Items]
Stock option, term								5 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Face amount					$ 179,592									$ 179,592
Purchase of common stock warrants	76,190	71,428
Common stock shares, authorized							2,500
Common stock, value							$ 51,750
Common stock value subscriptions							$ 25,000
Warrant description	The Company also amended the warrant to increase the number of shares of common stock underlying the warrant by another 4,762 (resulting in total shares underlying the warrant of 76,190) and each principal payment is increased from 1/4 of the outstanding not principal balance to 1/3 of the outstanding principal amount	The Company also amended the warrant to increase the number of shares of common stock underlying the warrant by another 4,762 (resulting in total shares underlying the warrant of 71,428) and each principal payment is increased from 1/5 of the outstanding not principal balance to 1/4 of the outstanding principal amount.
Shares issued	4,762	4,762
Cash proceeds				$ 152,390
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Common shares issued for cash, shares				116,000
Common shares issued for cash				$ 116,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Exercise of warrants				19,048
Subsequent Event [Member] | Convertible Senior Secured Note Payable and Warrants [Member]
Subsequent Event [Line Items]
Purchase of common stock warrants			66,666
Fair value adjustment of warrants			$ 60,000
Subsequent Event [Member] | Convertible Senior Secured Note Payable and Warrants [Member] | Warrant [Member]
Subsequent Event [Line Items]
Purchase of common stock warrants			4,761
Subsequent Event [Member] | Equity Option [Member] | Three Employees [Member]
Subsequent Event [Line Items]
Common stock, shares issued							18,663
Stock option, term							5 years
Share price							$ 20.70
Payments to purchase common stock							$ 155,250
Subsequent Event [Member] | Senior Notes [Member]
Subsequent Event [Line Items]
Face amount						$ 1,142,857		$ 1,142,857
Original issue discount rate						12.50%		12.50%
Debt payment terms						The Note carries a 12.5% interest rate with interest only payable monthly from April through August 2022
Debt interest rate						12.50%		12.50%
Proceeds from debt						$ 874,286
Original issue discount					$ 1,000,000	142,857		$ 142,857						1,000,000
Legal fees						$ 125,714
Monthly redemptions					110%
Mandatory prepayment of original principal amount, percentage					125%
Debt instrument, long term debt					$ 1,428,571									$ 1,428,571
Purchase of common stock warrants					57,142									57,142
Class of warrant exercise price per share					$ 0.0001									$ 0.0001